These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 25347948

  • 1. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
    Levinsen M, Rosthøj S, Nygaard U, Heldrup J, Harila-Saari A, Jonsson OG, Bechensteen AG, Abrahamsson J, Lausen B, Frandsen TL, Weinshilboum RM, Schmiegelow K.
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
    [Abstract] [Full Text] [Related]

  • 2. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K, Bretton-Meyer U.
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [Abstract] [Full Text] [Related]

  • 3. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
    Nielsen SN, Grell K, Nersting J, Frandsen TL, Hjalgrim LL, Schmiegelow K.
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
    Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K.
    Acta Paediatr; 1998 Jan; 87(1):108-11. PubMed ID: 9510461
    [Abstract] [Full Text] [Related]

  • 11. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T, Ebbesen M, Nersting J, Frandsen TL, Appell ML, Schmiegelow K.
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [Abstract] [Full Text] [Related]

  • 12. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Nielsen SN, Toksvang LN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Appell ML, Hjalgrim LL, Schmiegelow K.
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
    [Abstract] [Full Text] [Related]

  • 13. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
    Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J.
    J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
    [Abstract] [Full Text] [Related]

  • 14. Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia.
    Wennerstrand P, Mårtensson LG, Söderhäll S, Zimdahl A, Appell ML.
    Eur J Clin Pharmacol; 2013 Sep; 69(9):1641-9. PubMed ID: 23660772
    [Abstract] [Full Text] [Related]

  • 15. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
    Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS.
    Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
    [Abstract] [Full Text] [Related]

  • 16. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE.
    J Natl Cancer Inst; 1999 Dec 01; 91(23):2001-8. PubMed ID: 10580024
    [Abstract] [Full Text] [Related]

  • 17. TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia.
    Dreisig K, Brünner ED, Marquart HV, Helt LR, Nersting J, Frandsen TL, Jonsson OG, Taskinen M, Vaitkeviciene G, Lund B, Abrahamsson J, Lepik K, Schmiegelow K.
    Pediatr Hematol Oncol; 2021 Apr 01; 38(3):227-238. PubMed ID: 33205673
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
    Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N.
    Cancer Chemother Pharmacol; 2019 Feb 01; 83(2):341-348. PubMed ID: 30474703
    [Abstract] [Full Text] [Related]

  • 19. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K, Björk O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, Mäkipernaa A, Rosthøj S, Szumlanski C, Sørensen TM, Weinshilboum R.
    J Clin Oncol; 2003 Apr 01; 21(7):1332-9. PubMed ID: 12663723
    [Abstract] [Full Text] [Related]

  • 20. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
    Schmiegelow K, Nersting J, Nielsen SN, Heyman M, Wesenberg F, Kristinsson J, Vettenranta K, Schrøeder H, Weinshilboum R, Jensen KL, Grell K, Rosthoej S.
    Pediatr Blood Cancer; 2016 Dec 01; 63(12):2104-2111. PubMed ID: 27447547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.